The Prevalence of Pediatric Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in a Community‑Based Sample.
Jason, Leonard A, Katz, Ben Z, Sunnquist, Madison et al. · Child & youth care forum · 2020 · DOI
Quick Summary
Researchers studied over 10,000 children and teenagers in the Chicago area to find out how many have ME/CFS. They found that about 0.75% (roughly 1 in 133) young people have the condition, with higher rates among African American and Latino youth. Importantly, less than 5% of these children had been diagnosed before the study, meaning many young people with ME/CFS are going unrecognized by doctors.
Why It Matters
This study is important because it provides one of the first rigorous prevalence estimates of pediatric ME/CFS from a representative community sample rather than clinic populations, reducing bias toward severely affected or well-resourced patients. The finding that most affected youth remain undiagnosed highlights a critical diagnostic gap in pediatric medicine and underscores the need for improved clinical recognition and education. The higher prevalence in racial and ethnic minority youth suggests potential health equity disparities that warrant further investigation.
Observed Findings
Prevalence of pediatric ME/CFS was 0.75% in the community-based sample (approximately 1 in 133 youth).
Less than 5% of youth with ME/CFS had received a prior diagnosis.
Prevalence was higher among African American and Latinx youth compared to Caucasian youth.
Screening and diagnosis required comprehensive medical and psychiatric examinations to meet case definitions.
Inferred Conclusions
Pediatric ME/CFS is substantially underdiagnosed in community settings, with the vast majority of affected youth not recognized by healthcare providers.
Community-based prevalence estimates differ significantly from tertiary care-based estimates, likely due to reduced selection bias in community samples.
There is a critical need for improved clinical training and diagnostic tools to identify ME/CFS in children and adolescents across all demographic groups.
Remaining Questions
What are the specific barriers to diagnosis in children who remain undiagnosed with ME/CFS?
Why do African American and Latinx youth have higher prevalence rates, and are there genetic, environmental, or social determinants of health factors involved?
How does the prevalence in this Midwestern community compare to other geographic regions in the United States?
What This Study Does Not Prove
This study does not establish what causes ME/CFS or why certain racial/ethnic groups have higher prevalence rates. The cross-sectional design cannot determine whether undiagnosed youth had ME/CFS longer than diagnosed youth or establish temporal relationships. The study also does not prove that improved screening alone will lead to better health outcomes for young people with ME/CFS.